Botanix Pharmaceuticals Limited (AU:BOT) has released an update.
Botanix Pharmaceuticals Ltd has achieved a milestone with the FDA’s approval of Sofdra™, a new gel treatment for primary axillary hyperhidrosis, commonly known as excessive underarm sweating, for adults and children over 9. This marks the first new chemical entity to be approved for this condition, offering hope to an estimated 10 million Americans suffering from it. Botanix anticipates launching Sofdra in Q3 2024 with a patient experience program, expecting to generate its first revenues by early Q4 2024.
For further insights into AU:BOT stock, check out TipRanks’ Stock Analysis page.
